

Company Profile

Industry Sector: Biotechnology

Company Overview: GeneCopoeia, Inc. (GCI) is a biotechnology start-up company specializing in genomic-scale gene expression vector construction, gene expression, and protein expression/purification. The company has developed proprietary technology for refolding proteins expressed in *E. coli* as inclusion bodies. GCI utilizes this refolding technology to refold/purify proteins expressed as inclusion bodies in *E. coli* for developing important drug targets and protein drugs. GCI has developed a healthy protein drug pipeline including the recombinant p53-fusion protein for cancer currently funded by a SBIR Phase II grant, and a miniPlasmin protein for thromboembolic diseases currently funded by a SBIR Phase I grant.

Target Market(s): Pharma, Biotech industries and academic labs for reagent development; General health care for protein drug development.

Key Value Drivers

Technology*: We developed a p53 fusion protein drug candidate using a unique patented refolding technology, in conjunction with an efficient, specific, peptide-based delivery technology. Using *E. coli* inclusion bodies, we have refolded both the wild-type full-length p53 and the fusion protein gonadotropin-releasing hormone-p53 (GnRH-p53) into a stable tetrameric form. In addition, we have demonstrated that GnRH-p53 inhibits the growth of cancer cells both *in vitro* and *in vivo*.

Competitive Advantage: The p53 protein replacement cancer therapeutics is potentially less toxic and more effective than cancer drugs currently in the market.

Plan & Strategy: The long term objective of the company is to develop GnRH-p53 into an effective antineoplastic drug to treat GnRH-Receptor positive cancers. The company is currently seeking to raise sufficient fund from either a financial or a strategic investor in order to initiate the clinical development of the p53-fusion protein cancer drug candidate.

Management

Leadership:

Sun Lu, President and CEO
Xinli Lin, Vice President Research and Development
Peyton Hughes, Vice President Sales and Marketing

Scientific Advisory Board: The Company is currently assembling a scientific advisory board.

Product Pipeline

The following table list the company's major commercial reagent products and protein drug development:

Products	R&D	Commercial Sales
P53-fusion protein anticancer drug	√	
α1-antitrypsin for lung diseases	√	
>50,000 Full Length ORF Clones		√
>80 various expression vectors		√
All ORF in all expression vectors		√
Vector based shRNAs		√
Protein expression at Genome-scale		√
Lentivirus vector based production		√
Q-PCR kit/system		√
GPCR functional assay		√